{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:55:10Z","timestamp":1792716910996,"version":"4.5.0"},"reference-count":61,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,9,1]]},"DOI":"10.1001\/jamadermatol.2021.2779","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T12:14:09Z","timestamp":1628079249000},"page":"1066","source":"Crossref","is-referenced-by-count":45,"title":["Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis"],"prefix":"10.1001","volume":"157","author":[{"given":"Theresa","family":"Steeb","sequence":"first","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-University of Erlangen-N\u00fcrnberg (FAU), Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen\u2013European Metropolitan Region of N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Wessely","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-University of Erlangen-N\u00fcrnberg (FAU), Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen\u2013European Metropolitan Region of N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Petzold","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-University of Erlangen-N\u00fcrnberg (FAU), Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen\u2013European Metropolitan Region of N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titus J.","family":"Brinker","sequence":"additional","affiliation":[{"name":"Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruhr-University, Bochum, Germany"},{"name":"Institute of Dermatopathology, MVZ Corius DermPathBonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Eberhard Karls University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Eberhard Karls University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[{"name":"School of Business, Economics and Society, Friedrich-Alexander-University of Erlangen-N\u00fcrnberg (FAU), N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-University of Erlangen-N\u00fcrnberg (FAU), Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen\u2013European Metropolitan Region of N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus V.","family":"Heppt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-University of Erlangen-N\u00fcrnberg (FAU), Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen\u2013European Metropolitan Region of N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1, pt 2","key":"doi210036r1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1067\/mjd.2000.103342","article-title":"Epidemiology of actinic keratoses and squamous cell carcinoma.","volume":"42","author":"Salasche","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"1, pt 2","key":"doi210036r2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1067\/mjd.2000.103343","article-title":"Clinical presentation of actinic keratoses and squamous cell carcinoma.","volume":"42","author":"Moy","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"doi210036r3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/bjd.2007.156.issue-s3","article-title":"Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification.","volume":"156","author":"R\u00f6wert-Huber","year":"2007","journal-title":"Br J Dermatol"},{"issue":"11","key":"doi210036r4","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/cncr.v115:11","article-title":"Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"doi210036r5","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bjd.2013.169.issue-3","article-title":"The natural history of actinic keratosis: a systematic review.","volume":"169","author":"Werner","year":"2013","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi210036r6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2340\/00015555-2692","article-title":"Actinic keratosis, a chronic, progressive disease: understanding clinical gaps to optimise patient management.","volume":"97","author":"Cerio","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"doi210036r7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/jdv.2018.32.issue-4","article-title":"Defining the actinic keratosis field: a literature review and discussion.","volume":"32","author":"Figueras Nart","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"doi210036r8","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/jdv.13180","article-title":"Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis\u2014 International League of Dermatological Societies in cooperation with the European Dermatology Forum\u2014short version.","volume":"29","author":"Werner","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi210036r9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.2017.176.issue-1","article-title":"British Association of Dermatologists\u2019 guidelines for the care of patients with actinic keratosis 2017.","volume":"176","author":"de Berker","year":"2017","journal-title":"Br J Dermatol"},{"key":"doi210036r10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2021.05.056","article-title":"Guidelines of care for the management of actinic keratosis.","author":"Eisen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"doi210036r11","article-title":"Interventions for actinic keratoses.","volume":"12","author":"Gupta","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"doi210036r12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjd.2019.180.issue-1","article-title":"Local interventions for actinic keratosis in organ transplant recipients: a systematic review.","volume":"180","author":"Heppt","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi210036r13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jaad.2018.09.021","article-title":"Laser-assisted photodynamic therapy for actinic keratosis: a systematic review and meta-analysis.","volume":"80","author":"Steeb","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi210036r14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/ijd.2009.48.issue-5","article-title":"Effectiveness of 5-fluorouracil treatment for actinic keratosis\u2014a systematic review of randomized controlled trials.","volume":"48","author":"Askew","year":"2009","journal-title":"Int J Dermatol"},{"issue":"2","key":"doi210036r15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/bjd.12343","article-title":"Network meta-analysis of the outcome \u2018participant complete clearance\u2019 in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.","volume":"169","author":"Gupta","year":"2013","journal-title":"Br J Dermatol"},{"issue":"9","key":"doi210036r16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2217\/imt.12.93","article-title":"Randomized, vehicle-controlled trials of topical 5-fluorouracil therapy for actinic keratosis treatment: an overview.","volume":"4","author":"Rahvar","year":"2012","journal-title":"Immunotherapy"},{"issue":"3","key":"doi210036r17","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"doi210036r18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13643-016-0191-y","article-title":"Implementing PRISMA-P: recommendations for prospective authors.","volume":"5","author":"Moher","year":"2016","journal-title":"Syst Rev"},{"key":"doi210036r19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"11","key":"doi210036r20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"doi210036r21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13643-019-1156-8","article-title":"Long-term efficacy of interventions for actinic keratosis: protocol for a systematic review and network meta-analysis.","volume":"8","author":"Steeb","year":"2019","journal-title":"Syst Rev"},{"issue":"7","key":"doi210036r22","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1177\/0962280217746436","article-title":"A model for meta-analysis of correlated binary outcomes: the case of split-body interventions.","volume":"28","author":"Efthimiou","year":"2019","journal-title":"Stat Methods Med Res."},{"issue":"2","key":"doi210036r23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1365-2133.2010.09873.x","article-title":"Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study.","volume":"163","author":"Szeimies","year":"2010","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi210036r24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/bjd.2013.168.issue-4","article-title":"Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis.","volume":"168","author":"Dirschka","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi210036r25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2133.2011.10613.x","article-title":"Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo.","volume":"166","author":"Dirschka","year":"2012","journal-title":"Br J Dermatol"},{"issue":"12","key":"doi210036r26","first-page":"1432","article-title":"A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes.","volume":"10","author":"Foley","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"doi210036r27","first-page":"165","article-title":"Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream.","volume":"10","author":"Hanke","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"doi210036r28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized trial of four treatment approaches for actinic keratosis.","volume":"380","author":"Jansen","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"doi210036r29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.","volume":"57","author":"Jorizzo","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"doi210036r30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/(ISSN)1365-2133","article-title":"A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.","volume":"157","author":"Krawtchenko","year":"2007","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi210036r31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/(ISSN)1096-9101","article-title":"A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses.","volume":"38","author":"Ostertag","year":"2006","journal-title":"Lasers Surg Med"},{"issue":"9","key":"doi210036r32","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamadermatol.2015.0502","article-title":"Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial.","volume":"151","author":"Pomerantz","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"11","key":"doi210036r33","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/archderm.138.11.1498","article-title":"A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses.","volume":"138","author":"Stockfleth","year":"2002","journal-title":"Arch Dermatol"},{"issue":"12","key":"doi210036r34","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1001\/archderm.140.12.1542-a","article-title":"Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study.","volume":"140","author":"Stockfleth","year":"2004","journal-title":"Arch Dermatol"},{"issue":"3","key":"doi210036r35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1684\/ejd.2012.1707","article-title":"Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses.","volume":"22","author":"Stockfleth","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"5","key":"doi210036r36","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/bjd.2009.160.issue-5","article-title":"Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies.","volume":"160","author":"Hauschild","year":"2009","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi210036r37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1365-2133.2009.09377.x","article-title":"Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data.","volume":"162","author":"Szeimies","year":"2010","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi210036r38","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/bjd.2014.170.issue-5","article-title":"A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp.","volume":"170","author":"Zane","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi210036r39","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/bjd.2014.170.issue-5","article-title":"Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomized clinical trial.","volume":"170","author":"Zane","year":"2014","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi210036r40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory.","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"issue":"3","key":"doi210036r41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/jrsm.v11.3","article-title":"A comparison of Bayesian and frequentist methods in random-effects network meta-analysis of binary data.","volume":"11","author":"Seide","year":"2020","journal-title":"Res Synth Methods"},{"issue":"2","key":"doi210036r42","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jid.2020.06.021","article-title":"Interventions for actinic keratosis in nonscalp and nonface localizations: results from a systematic review with network meta-analysis.","volume":"141","author":"Steeb","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"25","key":"doi210036r43","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? comparing two approaches to multi-arm studies in network meta-analysis.","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Stat Med"},{"issue":"4","key":"doi210036r44","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/jrsm.v8.4","article-title":"Resolve conflicting rankings of outcomes in network meta-analysis: partial ordering of treatments.","volume":"8","author":"R\u00fccker","year":"2017","journal-title":"Res Synth Methods"},{"issue":"2","key":"doi210036r45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"doi210036r46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jrsm.1143","article-title":"Automated drawing of network plots in network meta-analysis.","volume":"7","author":"R\u00fccker","year":"2016","journal-title":"Res Synth Methods"},{"key":"doi210036r47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses.","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"doi210036r48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods.","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"doi210036r49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"doi210036r50","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"doi210036r52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis.","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"doi210036r53","doi-asserted-by":"publisher","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis.","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"doi210036r54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","article-title":"GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence.","volume":"108","author":"Brignardello-Petersen","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"doi210036r55","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3690","article-title":"Systematic literature review and network meta-analysis of the efficacy and acceptability of interventions in actinic keratoses.","volume":"101","author":"Ezzedine","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"doi210036r56","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12822","article-title":"Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: a network meta-analysis.","volume":"32","author":"Wu","year":"2019","journal-title":"Dermatol Ther"},{"issue":"6","key":"doi210036r57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096829","article-title":"A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe.","volume":"9","author":"Vegter","year":"2014","journal-title":"PLoS One"},{"key":"doi210036r58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2021.04.017","article-title":"Long-term recurrence rates of actinic keratosis: A systematic review and pooled analysis of randomized controlled trials.","author":"Steeb","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi210036r59","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/jdv.v34.1","article-title":"Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.","volume":"34","author":"Gollnick","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi210036r60","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamadermatol.2019.4212","article-title":"Core outcome set for actinic keratosis clinical trials.","volume":"156","author":"Reynolds","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi210036r61","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/jdv.12848","article-title":"Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin.","volume":"29","author":"Fern\u00e1ndez-Figueras","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi210036r51","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series","author":"Higgins","year":"2008"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2782523\/jamadermatology_steeb_2021_oi_210036_1631232140.48852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T11:26:04Z","timestamp":1631705164000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2782523"}},"subtitle":["A Systematic Review and Network Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.2779","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}